eligibility_summary
Key eligibility: Adults ≥18 with histologically confirmed CD20+ mature B‑cell neoplasm (large B‑cell lymphoma, follicular lymphoma, mantle cell lymphoma, CLL/SLL), relapsed/progressive/refractory after ≥2 prior lines, ECOG ≤2 (EU: <2). Exclude: other histologies, active CNS lymphoma, CNS disorders incl. seizures, recent HSCT (allo <180d, auto <90d) or cell therapy <90d, prior ≥G3 CRS/ICANS, uncontrolled infections, unresolved ≥G2 AEs (some exceptions). Other criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
AZD5492 is a subcutaneous bispecific T cell–engaging antibody (TCE). Mechanism: it binds CD20 on malignant B cells and engages CD8/TCR on T cells, redirecting cytotoxic T cells to CD20+ targets. This drives immune-synapse formation, TCR signaling, cytokine release, and perforin/granzyme-mediated killing, leading to depletion of CD20+ B cells. Targets: CD20+ mature B-cell malignancies (LBCL, FL, MCL, CLL/SLL) and effector CD8+ T cells. Pharmacodynamic focus includes T-cell activation and B-cell depletion, pathway engagement centers on TCR/CD8 signaling and tumor cell cytolysis.